Skip to content

Efficacy of magnesium prophylaxis on cardiac arrhythmia after by-pass coronary artery operations

Efficacy of magnesium prophylaxis on cardiac arrythmia after CABG

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201104106159N1
Enrollment
178
Registered
2011-05-11
Start date
2010-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: cardic arrhythmia. Condition 2: cardic arrhythmia. Condition 3: cardic arrhythmia. Condition 4: cardic arrhythmia. Condition 5: cardic arrhythmia. Ventricular tachycardia ??????????? ? ????? ?????? ??????????? ? ????? ???? ????? ????? ?????? ????? ????? ????

Interventions

Intervention 1: 87 patients were given 3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prio
Prevention
Placebo
87 patients were given 3 g of magnesium sulphate (MgSO4) [20 ml = 24.32 mEq/L Mg+2] in 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operati
87patients were given 100 cc of isotonic 0.9% solution over 2 hours intravenously at the following times: 12 hours prior to the operation, immediately following the operation, and on postoperative day

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria:l pateint candidate for coronary artery by-pass graft Exclusion criteria:renal and heart failure and history of arrythmia,used of anti arrythmic drug ,implantable cardiovertor deffibllirator

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Atrial fibrillation,atrial flutter.ventricular fibrillation,ventricular tackycardia,prematur ventricular complex,non sustained ventricular tackycardia. Timepoint: 24hour. Method of measurement: monitoring.

Secondary

MeasureTime frame
Cognitive status. Timepoint: daily. Method of measurement: Examination.;Coagebility status. Timepoint: daily. Method of measurement: lab.;Neurological status. Timepoint: daily. Method of measurement: examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Bahreman

Kermanshah University of Medical Sciences

DR-bahremand@kums.ac.ir+98 918 859 1451

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026